文献速递胃肠外科

减重代谢术后失访患者重新建立诊疗的结局与管理

Outcomes and Management of Re-Establishing Bariatric Patients.
PubMed 文献 · J Am Coll Surg · 2024-02-29

该回顾性队列研究纳入2018年7月至2022年12月间在减重代谢手术后停止常规随访、后重新到减重代谢门诊建立诊疗的400例患者,分析其就诊原因及后续治疗。结果显示复发性体重增加是三种术式患者重新就诊最常见原因,袖状胃切除术后修正手术率高于Roux-en-Y胃旁路术,而Roux-en-Y胃旁路术组内镜干预更常见,胰高血糖素样肽-1受体激动剂在Roux-en-Y胃旁路术患者中反应更好。

要点

  • 复发性体重增加是袖状胃切除、Roux-en-Y胃旁路术和可调节胃束带术后患者重新建立诊疗的最常见原因。
  • 袖状胃切除术后修正减重代谢手术率高于Roux-en-Y胃旁路术(16.9% vs 5.8%,p < 0.001)。
  • Roux-en-Y胃旁路术后内镜干预率高于袖状胃切除(17.5% vs 7.8%,p < 0.001)。

核心结论

  • 复发性体重增加是减重代谢术后患者重新建立诊疗的最常见原因。
  • 袖状胃切除术后修正减重代谢手术率高于Roux-en-Y胃旁路术,而Roux-en-Y胃旁路术组内镜干预更常见。
  • 抗肥胖药物尤其是胰高血糖素样肽-1受体激动剂在Roux-en-Y胃旁路术患者中反应优于袖状胃切除患者。

研究设计与样本

  • 回顾性队列研究,纳入2018年7月至2022年12月间在减重代谢手术后停止常规随访、后重新到减重代谢门诊建立诊疗的患者400例。
  • 纳入有袖状胃切除、Roux-en-Y胃旁路术和可调节胃束带术史的患者。

主要发现

  • 共纳入400例患者,女性占83.5%,重新建立减重代谢诊疗时平均年龄50.3 ± 12.2岁。
  • 177例(44.3%)为Roux-en-Y胃旁路术,154例(38.5%)为袖状胃切除,69例(17.2%)为可调节胃束带术。
  • 复发性体重增加是三种术式患者重新就诊的最常见原因:袖状胃切除81.2%,Roux-en-Y胃旁路术62.7%,可调节胃束带术65.2%(p < 0.001)。
  • 袖状胃切除患者接受修正减重代谢手术的比例高于Roux-en-Y胃旁路术患者(16.9% vs 5.8%,p < 0.001)。
  • Roux-en-Y胃旁路术患者接受内镜干预的比例高于袖状胃切除患者(17.5% vs 7.8%,p < 0.001)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Lifelong follow-up after metabolic and bariatric surgery (MBS) is necessary to monitor for patient outcomes and nutritional status. However, many patients do not routinely follow-up with their MBS team. We studied what prompted MBS patients to seek bariatric care after being lost to follow-up and the subsequent treatments they received. STUDY DESIGN: A retrospective cohort study of patients after MBS who had discontinued regular MBS follow-up but represented to the MBS clinic between July 2018 and December 2022 to re-establish care. Patients with a history of a sleeve gastrectomy (SG), Roux-En-Y gastric bypass (RYGB), and adjustable gastric banding (AGB) were included. RESULTS: We identified 400 patients (83.5% women, mean age 50.3 ± 12.2 years at the time of re-establishment of bariatric care), of whom 177 (44.3%) had RYGB, 154 (38.5%) had SG, and 69 (17.2%) had AGB. Overall, recurrent weight gain was the most common reason for presentation for all three procedures (81.2% in SG, 62.7% in RYGB, and 65.2% in AGB; p < 0.001). Patients who underwent SG were more likely to undergo a revision MBS compared with patients who underwent RYGB (16.9% vs 5.8%, p < 0.001), whereas patients who underwent RYGB were more likely to undergo an endoscopic intervention than patients who underwent SG (17.5% vs 7.8%, p < 0.001). The response to antiobesity medication agents, specifically glucagon-like peptide-1 receptor agonists drugs, was better in patients who underwent RYGB, than that in patients who underwent SG. CONCLUSIONS: This study highlights recurrent weight gain as the most common reason for patients after MBS seeking to re-establish care with the MBS team. SG had a higher rate of revision MBS than RYGB, whereas endoscopic interventions were performed more frequently in the RYGB group. Antiobesity medication agents, especially glucagon-like peptide-1 receptor agonists drugs, were more effective in patients who underwent RYGB.

来源:J Am Coll Surg,查看原文。版权归原作者所有。

引用

  1. Medhati P, Saleh OS, Nimeri A, et al. Outcomes and Management of Re-Establishing Bariatric Patients. J Am Coll Surg. 2024. PMID: 38421026. doi:10.1097/XCS.0000000000001062

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。